OBJECTIVE: Mitotane, a drug used to treat adrenocortical cancer (ACC), inhibits multiple enzymatic steps of adrenocortical steroid biosynthesis, potentially causing adrenal insufficiency.
INTRODUCTION
Mitotane has been employed in the treatment of adrenocortical cancer (ACC) over the last 50 years and is generally regarded as a toxic drug with a narrow therapeutic index (1, 2, 3, 4, 5, 6) . It is well known that mitotane is able to inhibit multiple enzymatic steps of adrenocortical steroid biosynthesis and for this reason mitotane has been used to treat Cushing's syndrome of different etiologies (7) . After the demonstration that adjunctive mitotane treatment following radical extirpation of ACC extends disease-free survival (8) , mitotane has been increasingly used in an adjuvant post-operative setting (9, 10, 11,12).
It is anticipated that patients adjuvantly treated with mitotane may develop adrenal insufficiency; thus, some clinicians prefer to initiate cortisol replacement concomitantly with mitotane (10,12).
However, there is still limited knowledge on the impact of chronic mitotane treatment on the function of the hypothalamic pituitary adrenal (HPA) axis. Since ACC is a very rare and aggressive tumor, the available studies did not focus on the consequences of chronic treatment with mitotane, but the issue of the mitotane-induced impairment of adrenal function is clinically relevant due to the improved prognosis of patients managed in referral centers following surgical removal of ACC (9, 11,13). An obvious goal of steroid replacement is avoiding an adrenal crisis that may be difficult to recognize because symptoms of adrenal insufficiency mimic mitotane toxicity (e.g. asthenia, nausea) (14, 5). Although it is wise to err in favor of over-replacement, these patients should be spared from the complications of excessive steroid treatment; a challenging aim due to the usual practice of giving high doses of steroids in mitotane-treated patients. The rationale for this stands in the cytochrome P4503A4 induction by mitotane that results in rapid and massive inactivation of administered hydrocortisone (15).
We have previously investigated the effects of mitotane on the endocrine system in patients treated adjunctively after complete ACC removal (16), showing that the drug was able to impair
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University of Turin's Institutional Research Information System and Open Access Institutional Repository adrenal hormone secretion and to increase cortisol-binding globulin (CBG). ACTH levels were found to be scattered with great individual variations. More recently, Gentilin and coworkers (17) showed that mitotane was able to affect corticotroph function and cell survival in the mouse pituitary cell line AtT20/D16v-F2 and in the primary cultures of human ACTH-secreting pituitary adenomas. Mitotane reduced cell viability and ACTH secretion by blocking the stimulatory effects of corticotropin releasing hormone (CRH) on cell viability, ACTH secretion, and POMC expression. These effects were apparent at mitotane doses greater than those usually necessary for reducing cortisol secretion in Cushing's syndrome, but still in the therapeutic range for ACC treatment. This study coupled with previous evidence that mitotane was able to impair thyrotrope cell viability, TSH secretory activity, TSH expression, and TRH responsivity in T-T1 cells (18), supports the hypothesis that mitotane may have direct inhibitory effects at the pituitary level.
Here we did a comprehensive assessment of the HPA axis in patients receiving mitotane as adjuvant treatment after radical resection of ACC to get insights on the pathophysiology of the HPA axis in this condition looking for markers of potential clinical interest.
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SUBJECTS AND METHODS
For the purpose of this study, we enrolled prospectively 16 consecutive patients who were managed at our center for adjuvant mitotane treatment between 2013 and 2015. Patients had radical (R0) resection of ACC, performed at least 1 year before (median 41 months) and followed by adjuvant All patients received the same mitotane formulation (Lysodren, 500 mg tablets) orally at a starting dose of 1 g daily, with progressive weekly increments up to 4-6 g daily, or the highest tolerated dose, aiming to reach concentrations between 14-20 mg/L (19) . When such or even higher concentrations were attained, doses were tapered with further individual dose adjustments guided by the results of mitotane measurement and toxicity assessment. Since the time when mitotane was commenced, all the patients received glucocorticoid replacement with a two-dose regimen of cortisone acetate (2/3 of dose in the morning at awakening, 1/3 of dose in the early afternoon). Due to the well-known enhanced metabolic clearance rate of glucocorticoids induced by mitotane (15) cortisone acetate was given at doses much higher than in Addison's disease. The dose of cortisone
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A group of 10 patients with primary adrenal insufficiency served as controls for the CRH test. In five patients hypoadrenalism had an autoimmune origin (Addison's disease), while in five patients it was due to bilateral adrenalectomy done in patients with previous Cushing's syndrome caused by ectopic ACTH secreting tumors, which were found and radically removed after adrenalectomy.
Study protocol
The study was done in an outpatient setting. A CRH test was performed between 0830 and 0900 h, after an overnight fast and omitting any hormone replacement in the morning. We deliberately set a minimum interval of 12 hours after the last dose of cortisone acetate. An antecubital vein was cannulated 30 min before the beginning of the test and blood samples were taken for measurement of plasma ACTH and serum cortisol at -15, 0, 15, 30, 45 and 60 after injection of human CRH (Ferring Arzneimittel GesmbH, Wien, Austria; 100 µg as an intravenous bolus). ACC patients also underwent routine laboratory evaluation, monitoring of mitotane concentrations and a hormonal work-up including determination of morning salivary cortisol, dehydroepiandrosterone sulfate (DHEAS), aldosterone, plasma renin activity (PRA), and cortisol binding globulin (CBG). In ACC patients, ACTH and cortisol levels were measured in the previous 12 months (a minimum of 6 measurements) and their correlations with supplemental glucocorticoid dose were analyzed. PAI patients underwent only a CRH test. Blood samples for serum and plasma hormone analyzes were collected in tubes that did not contain any additives or contained K2-EDTA, respectively. The serum was obtained by centrifuging the tubes at 3000 rpm for 15 min at room temperature, while the plasma by centrifuging the tubes at 3000 rpm for 15 min at 4 °C.
After separation from the red blood cells, serum and plasma were stored at 4-8°C if the assays were performed within 24 hours while, for longer storage periods, they were aliquoted and frozen at - 
Figures Legends

